Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Index | Nasdaq Biotechnology |
Investment focus | Equity, United States, Health Care |
Fund size | GBP 290 m |
Total expense ratio | 0.35% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 20.64% |
Inception/ Listing Date | 19 October 2017 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
Revision Company | Deloitte |
Fiscal Year End | 31 December |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Germany | 30% tax rebate |
Switzerland | ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Gilead Sciences, Inc. | 10.12% |
Amgen, Inc. | 9.04% |
Vertex Pharmaceuticals | 8.48% |
Regeneron Pharmaceuticals, Inc. | 7.34% |
AstraZeneca PLC ADR | 4.26% |
Alnylam Pharmaceuticals | 2.96% |
Biogen, Inc. | 1.97% |
argenx | 1.95% |
Sanofi | 1.57% |
Royalty Pharma | 1.43% |
United States | 78.70% |
Ireland | 1.45% |
Germany | 1.10% |
Other | 18.75% |
Health Care | 83.95% |
Other | 16.05% |
YTD | -13.63% |
1 month | -13.28% |
3 months | -15.98% |
6 months | -19.59% |
1 year | -8.49% |
3 years | -7.91% |
5 years | -3.79% |
Since inception (MAX) | +13.72% |
2024 | +0.60% |
2023 | -1.59% |
2022 | +0.40% |
2021 | +0.80% |
Volatility 1 year | 20.64% |
Volatility 3 years | 22.91% |
Volatility 5 years | 23.78% |
Return per risk 1 year | -0.41 |
Return per risk 3 years | -0.12 |
Return per risk 5 years | -0.03 |
Maximum drawdown 1 year | -23.05% |
Maximum drawdown 3 years | -23.05% |
Maximum drawdown 5 years | -30.57% |
Maximum drawdown since inception | -30.57% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | 2B70 | - - | - - | - |
Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
XETRA | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
Invesco Nasdaq Biotech UCITS ETF | 214 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 21 | 0.35% p.a. | Distributing | Sampling |